Q32 Bio halts trials amid job cuts and pivots to alopecia treatment
The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.
stocknews19h
3 Biotech Stocks Revolutionizing Healthcare
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors
Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics for targeted immune ...
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...